Bottom bounce! Aveo and Novartis reach a $300 million cooperation agreement

Source: Biovalley, August 19, 2015 Aveo oncology, a little-known company in the field of tumor drug research and development, has experienced a series of setbacks in the past few years Several of the company's promising cancer treatment drug programs have either failed in clinical trials or ended up at the feet of regulators A series of attacks also lowered the company's share price to an all-time low Now, however, Aveo seems to have a glimmer of hope Novartis, a pharmaceutical giant, has taken a fancy to an early drug research project of the company and reached a cooperation agreement with Aveo with a total value of 326 million US dollars According to the agreement, Novartis will pay Aveo an advance payment of US $15 million in exchange for its av-380 drug project Meanwhile, the agreement also provides a milestone bonus of US $311 million, including clinical research, approval and sales Av-380 is an antibody drug designed for the treatment of severe muscle atrophy and fat content reduction and other complications in cancer patients The drug blocks GDF15 to prevent cancer patients from developing severe weight loss Previous studies have shown that GDF15 plays an important role in the process of inflammation By blocking this protein, it can help patients improve this situation It is estimated that 5 million patients in the United States are suffering from this disease If av-380 can be successfully launched, it is expected to greatly reduce their suffering Although this agreement can not make the already troubled Aveo immediately bottom rebound, the cooperation of av-380 at least brings a glimmer of hope for its counter attack Previously, tivozanib, the company's number one hope star, failed in clinical research and was rejected twice by the FDA The company's former partners, astralas and Baijian, also left in succession, which made Aveo into an unprecedented predicament It also proves once again the truth that we should always speak with strength Can Aveo achieve a magnificent counter attack? There is still time to test.